AG0302-COVID‑19
AG0302-COVID‑19 is an investigational vaccine for the prevention of COVID-19, the disease caused by the SARS-CoV-2 virus. The vaccine is being developed by AnGes, Inc., a Japanese biopharmaceutical company, in collaboration with Osaka University and Takara Bio.
Development[edit | edit source]
The development of AG0302-COVID‑19 began in early 2020, following the global outbreak of the COVID-19 pandemic. The vaccine is based on DNA vaccine technology, which uses a small, circular piece of DNA called a plasmid that has been engineered to produce a protein found in SARS-CoV-2.
Clinical Trials[edit | edit source]
The vaccine entered Phase I clinical trials in Japan in June 2020, with the aim of testing its safety and efficacy in a small group of volunteers. The results of these trials are yet to be published.
Mechanism of Action[edit | edit source]
AG0302-COVID‑19 works by introducing a piece of DNA into the body that encodes for a protein found in SARS-CoV-2. This protein triggers an immune response, which is intended to protect against future infection with the virus.
Potential Side Effects[edit | edit source]
As with all vaccines, AG0302-COVID‑19 may cause side effects. These are most likely to include common vaccine side effects such as pain at the injection site, fever, and muscle aches.
See Also[edit | edit source]
References[edit | edit source]
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.Contributors: Prab R. Tumpati, MD